Perampanel
Perampanel
Perampanel (pronunciation: /pɛrˈæmpænɛl/) is a non-competitive AMPA receptor antagonist that is used primarily in the treatment of epilepsy. It is marketed under the brand name Fycompa.
Etymology
The term "Perampanel" is derived from the chemical name 2-(2-Oxo-1-phenyl-5-pyridin-2-yl-1,2-dihydropyridin-3-yl)benzonitrile. The name is a portmanteau of parts of the chemical name.
Usage
Perampanel is used as an adjunctive therapy in the treatment of partial-onset seizures and primary generalized tonic-clonic seizures in patients with epilepsy. It is also used for the treatment of seizures associated with Lennox-Gastaut syndrome in patients 12 years of age and older.
Mechanism of Action
Perampanel selectively antagonizes the action of glutamate at the AMPA receptor, thereby reducing neuronal excitation. This action is believed to contribute to its efficacy in treating seizures.
Side Effects
Common side effects of Perampanel include dizziness, fatigue, irritability, falls, nausea, weight gain, vertigo, and ataxia. Serious side effects may include aggression, anger, and suicidal thoughts or behaviors.
Related Terms
External links
- Medical encyclopedia article on Perampanel
- Wikipedia's article - Perampanel
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski